The First Shot in a Highly Targeted Strategy

摘要

For biologists, it's a new way of doing business. Last week, the National Institute of Allergy and Infectious Diseases (NIAID) unveiled a highly targeted strategy to tackle immunological puzzles bedeviling AIDS vaccine research. Rattier than rely on individual researchers to submit grant proposals, NIAID is planning to bankroll a collaboration called the Center for HIV/AIDS Vaccine Immunol- ogy (CHAVI) to focus on problems already identified as key obstacles to the development of an effective AIDS vaccine. The proposed venture could pump at least $300 million into the field over the next 7 years. And more such initiatives are on the way.